Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer

Study summary

This research study is evaluating a behavioral intervention designed to help people with advanced lung cancer manage dyspnea (i.e., breathlessness or shortness-of-breath).

Ask AI to explain this study

Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedDyspnea Intervention and Usual Care

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 27, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Massachusetts General Hospital

Study sponsor

Study overview

What this study is about

Purpose: Supportive Care
Study type: Interventional
Phase: Not applicable
Sponsor: Massachusetts General Hospital
Interventions being studied: Behavioral: Dyspnea Intervention; Other: Usual Care

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Supportive or behavioral care→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

A diagnosis of either NSCLC, SCLC, or mesothelioma, not being treated with curative intent
Self-reported shortness of breath (a score of 2 or greater on the Modified Medical Research Council Dyspnea Scale)
Eastern Cooperative Oncology Group (ECOG) Performance Status from 0 (asymptomatic) to 2 (symptomatic and in bed \<50% of day)
The ability to read and respond to questions English
Primary cancer care at the Massachusetts General Hospital (MGH) Cancer Center or Dana-Farber Cancer Institute (DFCI)
Age \>18 years

Reasons someone may not be able to joinExclusion criteria

Cognitive or psychiatric conditions prohibiting study consent or participation.
A treating clinician who reports that the patient is inappropriate for the study

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Massachusetts General HospitalBoston, Massachusetts
Dana Farber Cancer InstituteBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 27, 2025. Always confirm current availability with the study team.

View original record ↗